MX2008010082A - Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad. - Google Patents
Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad.Info
- Publication number
- MX2008010082A MX2008010082A MX2008010082A MX2008010082A MX2008010082A MX 2008010082 A MX2008010082 A MX 2008010082A MX 2008010082 A MX2008010082 A MX 2008010082A MX 2008010082 A MX2008010082 A MX 2008010082A MX 2008010082 A MX2008010082 A MX 2008010082A
- Authority
- MX
- Mexico
- Prior art keywords
- weight
- pharmaceutical composition
- orlistat
- agent
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 133
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 88
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 86
- 229960001243 orlistat Drugs 0.000 title claims abstract description 77
- 239000000843 powder Substances 0.000 title claims abstract description 29
- 208000008589 Obesity Diseases 0.000 title claims abstract description 8
- 235000020824 obesity Nutrition 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 33
- 239000004094 surface-active agent Substances 0.000 claims abstract description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 24
- 239000008101 lactose Substances 0.000 claims abstract description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 21
- 239000004615 ingredient Substances 0.000 claims abstract description 20
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims abstract description 19
- 239000007921 spray Substances 0.000 claims abstract description 19
- 239000006096 absorbing agent Substances 0.000 claims abstract description 18
- 239000000314 lubricant Substances 0.000 claims abstract description 18
- 239000003085 diluting agent Substances 0.000 claims abstract description 13
- 239000007903 gelatin capsule Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 8
- 229930195725 Mannitol Natural products 0.000 claims abstract description 8
- 239000000594 mannitol Substances 0.000 claims abstract description 8
- 235000010355 mannitol Nutrition 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 5
- 235000019698 starch Nutrition 0.000 claims abstract description 5
- 229940023144 sodium glycolate Drugs 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 24
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 24
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 24
- 239000000454 talc Substances 0.000 claims description 24
- 235000012222 talc Nutrition 0.000 claims description 24
- 229910052623 talc Inorganic materials 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 239000008109 sodium starch glycolate Substances 0.000 claims description 20
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 20
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 20
- 239000007884 disintegrant Substances 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 239000003945 anionic surfactant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical group [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000002250 absorbent Substances 0.000 abstract 1
- 229910052938 sodium sulfate Inorganic materials 0.000 abstract 1
- 235000011152 sodium sulphate Nutrition 0.000 abstract 1
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 16
- 239000002775 capsule Substances 0.000 description 15
- 229940033134 talc Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 9
- 229940002552 xenical Drugs 0.000 description 9
- 238000003860 storage Methods 0.000 description 8
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 6
- 102000019280 Pancreatic lipases Human genes 0.000 description 6
- 108050006759 Pancreatic lipases Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940116369 pancreatic lipase Drugs 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- -1 fatty acid ester Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005563 spheronization Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NKQFKJYKCVDLPT-KHPPLWFESA-N (4-methyl-2-oxochromen-7-yl) (z)-octadec-9-enoate Chemical compound CC1=CC(=O)OC2=CC(OC(=O)CCCCCCC\C=C/CCCCCCCC)=CC=C21 NKQFKJYKCVDLPT-KHPPLWFESA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229920000080 bile acid sequestrant Polymers 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012976 trial formulation Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2007002287A CL53426B (fr) | 2007-08-06 | 2007-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008010082A true MX2008010082A (es) | 2009-04-17 |
Family
ID=51359501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008010082A MX2008010082A (es) | 2007-08-06 | 2008-08-06 | Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad. |
Country Status (7)
| Country | Link |
|---|---|
| CL (1) | CL53426B (fr) |
| CR (1) | CR10132A (fr) |
| DO (1) | DOP2008000021A (fr) |
| MX (1) | MX2008010082A (fr) |
| PA (1) | PA8786701A1 (fr) |
| PE (1) | PE20091224A1 (fr) |
| SV (1) | SV2009002991A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL216542B1 (pl) * | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
-
2007
- 2007-08-06 CL CL2007002287A patent/CL53426B/es active
- 2007-10-25 PE PE2007001452A patent/PE20091224A1/es active IP Right Grant
-
2008
- 2008-04-10 DO DO2008000021A patent/DOP2008000021A/es unknown
- 2008-07-01 PA PA20088786701A patent/PA8786701A1/es unknown
- 2008-07-07 CR CR10132A patent/CR10132A/es not_active Application Discontinuation
- 2008-07-31 SV SV2008002991A patent/SV2009002991A/es unknown
- 2008-08-06 MX MX2008010082A patent/MX2008010082A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002287A1 (fr) | 2007-12-14 |
| DOP2008000021A (es) | 2009-11-30 |
| CR10132A (es) | 2008-10-28 |
| SV2009002991A (es) | 2009-04-16 |
| PA8786701A1 (es) | 2009-04-23 |
| CL53426B (fr) | 2016-11-28 |
| PE20091224A1 (es) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3048688T3 (en) | High dosage strength tablets of rucaparib | |
| CA2474674C (fr) | Preparation solide contenant une forme monocristalline | |
| KR100634253B1 (ko) | 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법 | |
| JP4868695B2 (ja) | 崩壊性が良好な経口製剤 | |
| SA517390473B1 (ar) | أشكال جرعة صلبة من بالبوسيكليب | |
| JP2005522444A (ja) | アルカリ金属の添加により安定化させたアトーバスタチン製剤 | |
| KR20160013068A (ko) | 세니크리비록 조성물 및 이들을 만들고 이용하는 방법 | |
| JP2012522764A (ja) | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 | |
| CA2720658A1 (fr) | Formulations ameliorees pour des ingredients pharmaceutiques actifs faiblement permeables | |
| MX2007009571A (es) | Tabletas con dispersion mejorada de la sustancia del farmaco. | |
| EP2217241B1 (fr) | Granulation par voie humide à l'aide d'un séquestrant d'eau | |
| WO2009039157A2 (fr) | Formulations pharmaceutiques d'orlistat | |
| KR20100099113A (ko) | 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물 | |
| EP2021002A2 (fr) | Composition pharmaceutique | |
| CN1946426B (zh) | 用于口服施用HMG-CoA还原酶抑制剂的持续释放制剂和其制备方法 | |
| US20020028248A1 (en) | Rapid-release microdispersible ecadotril preparation | |
| EP2389927A1 (fr) | Formulations pharmaceutiques de rasagiline | |
| US8062664B2 (en) | Process for preparing formulations of lipid-regulating drugs | |
| MX2008010082A (es) | Composicion farmaceutica en la forma de polvos encapsulados que comprende orlistat, procedimiento de preparacion de la composicion y su uso para el tratamiento de la obesidad. | |
| JP2004536826A (ja) | プラバスタチンを含む安定な薬剤組成物 | |
| CN111529500B (zh) | 一种提高谷维素溶解度的药物组合物及其制备方法 | |
| KR100700472B1 (ko) | 프로펜 함유 제약 혼합물 | |
| WO2005115346A2 (fr) | Composition contenant de la risperidone | |
| KR100958197B1 (ko) | 올리스타트를 포함하는 약학적 조성물 및 이의 제조 방법 | |
| PL216542B1 (pl) | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |